Search

Your search keyword '"Schaefer, Eric S."' showing total 12 results
Start Over Author "Schaefer, Eric S."
12 results on '"Schaefer, Eric S."'

4. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.

Author

So, Raymond J., Hidalgo Lopez, Julio C., Ballestas, Samir A., Klein, Adam M., Steuer, Conor, Shin, Dong M., Abousaud, Marin, Teng, Yong, Saba, Nabil F., Tkaczuk, Andrew T., Schaefer, Eric S., Seiwert, Tanguy Y., McClellan, Kim, and Best, Simon R.

Abstract

Objectives: Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP are limited. This study's objective was to characterize disease response of pulmonary RRP to systemic bevacizumab. Methods: A retrospective review was performed to identify patients with pulmonary RRP seen at three medical institutions. Clinical symptoms, CT findings, and disease response were compared before and after initiation of systemic bevacizumab therapy. Disease response was categorized as complete response, partial response, stabilization, or progression for each subsite involved by papilloma. Results: Of the 12 pulmonary RRP patients treated with systemic bevacizumab, 4 (33.3%) were male, and 11 (91.7%) were juvenile‐onset RRP patients. All presented with laryngeal, tracheal, and pulmonary RRP. The median (range) age at first bevacizumab infusion was 48.1 (19.5–70.2) years. Progression to pulmonary malignancy was identified in 3 (25.0%) patients, 2 before initiation of and 1 after complete cessation of bevacizumab therapy. Clinical symptoms such as dyspnea (75.0% vs. 25.0%; p = 0.01) and dysphagia and/or odynophagia (33.3 vs. 0.0%; p = 0.03) were significantly decreased following bevacizumab therapy. Compared with pre‐treatment baseline, 9 (75.0%) patients experienced a stable‐to‐partial response in the lungs to systemic bevacizumab, and 10 (83.3%) experienced partial‐to‐complete responses in the larynx and trachea. Conclusion: Systemic bevacizumab is effective in stabilizing progression in even the most severe cases of RRP, with both a dramatic reduction in laryngeal and tracheal disease as well as a stable‐to‐partial response of pulmonary involvement in a majority of patients. Level of Evidence: 4 Laryngoscope, 134:577–581, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement

Author

So, Raymond J., primary, Hidalgo Lopez, Julio C., additional, Ballestas, Samir A., additional, Klein, Adam M., additional, Steuer, Conor, additional, Shin, Dong M., additional, Abousaud, Marin, additional, Teng, Yong, additional, Saba, Nabil F., additional, Tkaczuk, Andrew T., additional, Schaefer, Eric S., additional, Seiwert, Tanguy Y., additional, McClellan, Kim, additional, and Best, Simon R., additional

Published
2023
Full Text
View/download PDF

8. A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).

Author

Schaefer, Eric S., primary, Camidge, D. Ross, additional, Yoh, Kiyotaka, additional, Zer, Alona, additional, Hernandez Guerrero, Tatiana, additional, Bar, Jair, additional, Okuma, Yusuke, additional, Peguero, Julio Antonio, additional, De Miguel, Maria, additional, Moskovitz, Mor Tal, additional, Morgensztern, Daniel, additional, Jeffries, Shawn, additional, Wang, Lan, additional, Lally, Satwant, additional, Conn, Christopher, additional, Xin, Xiaohua, additional, Jeng, Edwin E., additional, and Johnson, Melissa Lynne, additional

Published
2021
Full Text
View/download PDF

11. First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.

Author

Morgensztern, Daniel, Ready, Neal E., Johnson, Melissa Lynne, Dowlati, Afshin, Choudhury, Noura J., Carbone, David Paul, Schaefer, Eric S., Arnold, Susanne M., Puri, Sonam, Piotrowska, Zofia, Hegde, Aparna Madhukeshwar, Chiang, Anne C., Iams, Wade Thomas, Tolcher, Anthony W., Nosaki, Kaname, Zha, Jiuhong, Li, Rui, Hingorani, Pooja, Jeng, Edwin E., and Furqan, Muhammad

Published
2023
Full Text
View/download PDF

12. The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer.

Author

Page, Ray D., Argento, A. Christine, Nash, David B., Skoufalos, Alexandria, and Schaefer, Eric S.

Subjects
CLINICAL medicine, LUNG cancer, MEDICAL quality control, MEDICAL protocols, PROGNOSIS, PROTEOMICS, KEY performance indicators (Management)
Abstract

Purpose: The Oncology Care Model (OCM) is a payment model from the Centers for Medicare and Medicaid Services designed to reduce costs and improve quality in cancer care. Key components of quality for the OCM originate from the 13-component cancer care plan. We surveyed the literature to understand the value of prognosis in OCM-directed planning for non-small-cell lung cancer (NSCLC) care and to investigate how the results of a prognostic, proteomic biomarker test, the VeriStrat test, can help OCM-participating providers meet the specific quality measures.Design: A targeted literature review was supplemented by real-world author experience.Methodology: Available MEDLINE-indexed literature on the topic of lung cancer prognosis and cancer care planning (1997-2017) were reviewed. Authors also included relevant commentary based on their own real-world experience with VeriStrat testing and prognostic conversations.Results: There was near-universal consensus in guidelines and literature about the critical importance of early, candid, and ongoing physician-patient discussions about prognosis, which informs most components of the OCM care plan. The VeriStrat test has been shown to provide accurate predictions of outcomes in all lines of therapy and in various treatments for patients with NSCLC, including chemotherapies and EGFR-TKI therapies.Conclusion: Accurate prognostic estimates, such as those provided by the VeriStrat test, are useful for predicting and documenting expected response to treatment, avoiding ineffective and costly overtreatment and for facilitating meaningful conversations with NSCLC patients about the timing of best supportive care and hospice care when appropriate, thereby improving cancer care planning and quality scores. [ABSTRACT FROM AUTHOR]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results